Confirmation of the protective effect of iNOS in an independent cohort of Parkinson disease

S Hague; T Peuralinna; J Eerola; O Hellström; P J Tienari; A B Singleton

doi:10.1212/01.wnl.0000110191.38152.29

Confirmation of the protective effect of iNOS in an independent cohort of Parkinson disease

Neurology. 2004 Feb 24;62(4):635-6. doi: 10.1212/01.wnl.0000110191.38152.29.

Authors

S Hague¹, T Peuralinna, J Eerola, O Hellström, P J Tienari, A B Singleton

Affiliation

¹ Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD 20892, USA.

PMID: 14981185
DOI: 10.1212/01.wnl.0000110191.38152.29

Abstract

Nitric oxide is a biologic messenger molecule involved in a diverse range of physiologic processes. An exon 22 inducible nitric oxide synthase genotype has recently been reported to be protective against Parkinson disease in a European cohort. The authors confirm the protective effect of this genotype (OR = 0.5, 95% CI 0.27 to 0.93) in an independent Finnish case-control series.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Alleles
Case-Control Studies
Exons / genetics
Female
Finland / epidemiology
Genetic Predisposition to Disease
Genotype
Haplotypes
Humans
Linkage Disequilibrium
Male
Middle Aged
Nitric Oxide / physiology*
Nitric Oxide Synthase / physiology*
Nitric Oxide Synthase Type II
Parkinson Disease / enzymology*
Parkinson Disease / epidemiology

Substances

Nitric Oxide
NOS2 protein, human
Nitric Oxide Synthase
Nitric Oxide Synthase Type II